← Patent-cliff monitor Biotechnology company that discovers, develops, manufactures and commercializes therapeutic products for serious or life-threatening medical conditions. Disease areas include oncology, immunology, ophthalmology, metabolism and virology. Genentech has been a member of the Roche Group since 2009.
Company AngelList URL https://angel.co/genentech CAGE Code 1HZ12 Legal Name Genentech, Inc. Company Operating Status Active Crunchbase URL https://www.crunchbase.com/organization/genentech Facebook URL https://facebook.com/genentech Full Address 1 DNA Way, South San Francisco, CA 94080, United States Instagram URL https://instagram.com/genentech
55 upcoming patent cliffs Drug Ingredient Type Cliff
Activase alteplase Biologic Nov 1999 Activase alteplase Biologic Nov 1999 Pulmozyme dornase alfa Biologic Dec 2005 Rituxan rituximab Biologic Nov 2009 Rituxan rituximab Biologic Nov 2009 TNKase tenecteplase Biologic Jun 2012 Cathflo Activase alteplase Biologic Sep 2013 Xolair omalizumab Biologic Jun 2015 Avastin bevacizumab Biologic Feb 2016 Avastin bevacizumab Biologic Feb 2016 Actemra tocilizumab Biologic Jan 2022 Actemra tocilizumab Biologic Jan 2022 Actemra tocilizumab Biologic Jan 2022 Perjeta pertuzumab Biologic Jun 2024 Kadcyla ado-trastuzumab emtansine Biologic Feb 2025 Kadcyla ado-trastuzumab emtansine Biologic Feb 2025 Actemra tocilizumab Biologic Oct 2025 Gazyva obinutuzumab Biologic Nov 2025 Tecentriq atezolizumab Biologic May 2028 Lucentis ranibizumab Biologic Oct 2028 ERIVEDGE VISMODEGIB Small mol. Dec 2028 Herceptin trastuzumab Biologic Feb 2029 Ocrevus ocrelizumab Biologic Mar 2029 Rituxan Hycela rituximab and hyaluronidase human Biologic Jun 2029 Rituxan Hycela rituximab and hyaluronidase human Biologic Jun 2029 Hemlibra emicizumab-kxwh Biologic Nov 2029 Hemlibra emicizumab-kxwh Biologic Nov 2029 Hemlibra emicizumab-kxwh Biologic Nov 2029 Hemlibra emicizumab-kxwh Biologic Nov 2029 Lucentis ranibizumab Biologic Mar 2030 Xolair omalizumab Biologic Sep 2030 Xolair omalizumab Biologic Sep 2030 ROZLYTREK ENTRECTINIB Small mol. Oct 2030 Actemra tocilizumab Biologic Nov 2030 Herceptin Hylecta trastuzumab and hyaluronidase-oysk Biologic Feb 2031 Tecentriq atezolizumab Biologic Mar 2031 Polivy polatuzumab vedotin-piiq Biologic Jun 2031 Phesgo pertuzumab, trastuzumab, and hyaluronidase-zzxf Biologic Jun 2032 Phesgo pertuzumab, trastuzumab, and hyaluronidase-zzxf Biologic Jun 2032 Enspryng satralizumab-mwge Biologic Aug 2032 Polivy polatuzumab vedotin-piiq Biologic Sep 2032 Susvimo ranibizumab Biologic Oct 2033 Vabysmo faricimab-svoa Biologic Jan 2034 Lunsumio mosunetuzumab-axgb Biologic Dec 2034 Lunsumio mosunetuzumab-axgb Biologic Dec 2034 Hemlibra emicizumab-kxwh Biologic Mar 2035 Columvi glofitamab-gxbm Biologic Jun 2035 Columvi glofitamab-gxbm Biologic Jun 2035 Xolair omalizumab Biologic Aug 2035 Xolair omalizumab Biologic Aug 2035 Xolair omalizumab Biologic Aug 2035 Xolair omalizumab Biologic Aug 2035 Hemlibra emicizumab-kxwh Biologic Jan 2036 Piasky crovalimab-akkz Biologic Jun 2036 Vabysmo faricimab-svoa Biologic Jul 2036 Tecentriq Hybreza atezolizumab and hyaluronidase-tqjs Biologic Sep 2036 Ocrevus Zunovo ocrelizumab and hyaluronidase-ocsq Biologic Sep 2036 COTELLIC COBIMETINIB FUMARATE Small mol. Dec 2036 TNKase tenecteplase Biologic Feb 2037 Lunsumio Velo mosunetuzumab-axgb Biologic Dec 2037 Lunsumio Velo mosunetuzumab-axgb Biologic Dec 2037 ITOVEBI INAVOLISIB Small mol. Jun 2038 ITOVEBI INAVOLISIB Small mol. Jun 2038 ROZLYTREK ENTRECTINIB Small mol. Jul 2038 ROZLYTREK ENTRECTINIB Small mol. Jul 2038 XOFLUZA BALOXAVIR MARBOXIL Small mol. Oct 2039 XOFLUZA BALOXAVIR MARBOXIL Small mol. Oct 2039 XOFLUZA BALOXAVIR MARBOXIL Small mol. Oct 2039 EVRYSDI RISDIPLAM Small mol. Apr 2041 EVRYSDI RISDIPLAM Small mol. Apr 2041 XOFLUZA BALOXAVIR MARBOXIL Small mol. Apr 2041 XOFLUZA BALOXAVIR MARBOXIL Small mol. Apr 2041 XOFLUZA BALOXAVIR MARBOXIL Small mol. Apr 2041 Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.